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Kidney and pancreas transplantation in 2005 improved
in quantity and outcome quality, despite the increasing
average age of kidney graft recipients, with 56% aged
50 or older. Geography and ABO blood type contribute
to the discrepancy in waiting time among the deceased
donor (DD) candidates. Allocation policy changes are
decreasing the median times to transplant for pedi-
atric recipients. Overall, 6% more DD kidney trans-
plants were performed in 2005 with slight increases
in standard criteria donors (SCD) and expanded cri-
teria donors (ECD). The largest increase (39%) was
in donation after cardiac death (DCD) from non-ECD
donors. These DCD, non-ECD kidneys had equivalent
outcomes to SCD kidneys. 1-, 3- and 5-year unadjusted
graft survival was 91%, 80% and 70% for non-ECD-
DD transplants, 82%, 68% and 53% for ECD-DD grafts,
and 95%, 88% and 80% for living donor kidney trans-
plants. In 2005, 27% of patients were discharged with-
out steroids compared to 3% in 1999. Acute rejection
decreased to 11% in 2004. There was a slight increase
in the number of simultaneous pancreas-kidney trans-
plants (895), with fewer pancreas after kidney trans-
plants (343 from 419 in 2004), and a stable number of
pancreas alone transplants (129). Pancreas underuti-
lization appears to be an ongoing issue.
Key words: Graft survival, kidney transplantation, liv-
ing donors, OPTN, pancreas transplantation, SRTR
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Introduction
With 91 441 renal transplant recipients entering 2005 with
a functioning graft, the care of the renal transplant recipient
is now an important concern for all physicians in the United
States. As the average age and comorbidities of these re-
cipients increases, so does their need for coordinated care
between the transplant center and community physicians
from all specialties. In this article, based on the 2006 Organ
Procurement and Transplantation Network/Scientific Reg-
istry of Transplant Recipients (OPTN/SRTR) Annual Report,
we review the standard kidney and pancreas transplant
candidate and recipient data tables, and provide an update
on OPTN policies affecting kidney and pancreas transplan-
tation in 2005. The Health Resources and Services Admin-
istration (HRSA) Organ Donation Breakthrough Collabora-
tive and its impact on renal-pancreas transplantation are
also discussed.
OPTN policy changes in 2005
Recent modifications to the system for kidney allocation
in the United States include (1) changes in the priority as-
signed to pediatric candidates (i.e. less than 18 years old),
and (2) implementation of a study to start candidate waiting
time accrual from the initiation of dialysis.
(1) On September 28, 2005, the kidney allocation system
was modified to provide priority for the allocation of stan-
dard criteria deceased donor (DD) kidneys from donors less
than 35 years to pediatric candidates (listed prior to age 18)
at each of the local, regional and national levels of organ dis-
tribution. The intent of this modification is to allocate donor
kidneys better suited to children immediately to address
established goals of rapid transplantation for pediatric can-
didates, with minimal impact on adult transplantation. The
modified pediatric candidate priority falls in the allocation
algorithm after zero antigen-mismatched candidates, sen-
sitized candidates (PRA ≥ 80%) who otherwise would rank
highest in allocation priority, combined kidney/nonrenal or-
gan candidates and prior living organ donors, but before
kidney paybacks. The system no longer uses pediatric al-
location points, except in the allocation of zero antigen-
mismatched kidneys, and to maintain the current one point
preference for younger pediatric versus adolescent candi-
dates in allocating mismatched kidneys from donors less
than 35 years.
(2) On April 29, 2006, the OPTN implemented a volun-
tary pilot study to assess the impact on kidney allocation
from permitting kidney waiting time accrual to commence
from the time of initiation of chronic maintenance dialysis
once listed as an active transplant candidate, even if this
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time pre-dates the date of listing, and for repeat transplant
candidates, from the date the candidate returns to chronic
maintenance dialysis after graft failure once relisted, even
if this time pre-dates the date of relisting. The intent of the
study is to test the effect of a change in the definition of
waiting time on access to transplantation within participat-
ing donation service areas (DSAs). The study still allows
adult candidates to begin accumulating their waiting time
prior to their initiation of dialysis once listed and with a cre-
atinine clearance (CrCl) <20 mL/min. Waiting time is not
granted retrospectively to the date of measured or calcu-
lated CrCl < 20 mL/min. Pediatric candidates continue to
accrue waiting time from time of listing if they have not
started dialysis and regardless of their creatinine clearance
level. Two DSAs are presently participating in the study;
a third DSA will be enrolled pending computer program-
ming. Other DSAs using the standard, national system for
kidney allocation and distribution that wish to participate
in the study may do so with the agreement of all kidney
transplant programs served by the DSA and submission of
a request to participate to the OPTN.
Definitions of donor type
With the increase in use of kidneys from both expanded
criteria donors (ECD) and donors after cardiac death (DCD),
there has developed uncertainty regarding the usage of
these terms in kidney transplantation. While a common
nomenclature has appeared to evolve, the precise meaning
of these terms in common usage often depends upon the
context in which they are used.
ECD are any donor aged 60 years or older, or over 50
years old with at least two of the following conditions: hy-
pertension history, serum creatinine >1.5 mg/dL or cause
of death from cerebrovascular accident. DCD are distin-
guished from donors with brain death. These may be re-
ferred to as donors after brain death (DBD) or non-DCD
donors. Standard criteria donors (SCD), the most common
type, are those who neither meet the criteria for ECD nor
DCD. DCD donors may be divided into those who would
otherwise fit into the ECD or SCD categories based on the
ECD definition, and these donors are frequently designated
as ECD-DCD and DCD/non-ECD, respectively (Figure 1).
These four categories are outlined in Table 1.
In the SRTR Annual Report data tables for kidney trans-
plantation, other than Table 5.4, donors are separated into
living donor, non-ECD and ECD. For these tables, non-ECD
includes any donor that does not meet ECD criteria (all
SCD and DCD/non-ECD). Transplants from DCD donors
who meet the ECD criteria (ECD-DCD) are counted as ECD
transplants.
It is, however, important to note that this nomenclature is
not uniform in practice or in the literature. As stated above,
the distinction between ECD/non-ECD commonly provides
for the inclusion of appropriate DCD transplants in both
Note: Not drawn to scale. Source: SRTR.
Figure 1: Categories within the deceased kidney donor pool:
SCD, ECD, DCD.
groups, and analyses of DCD versus non-DCD transplants
similarly include ECD transplants in the appropriate groups.
However, it is also common, especially when examining
utilization patterns, to split DDs by SCD, ECD and DCD (for
an example, see discussion of the HRSA Collaboratives,
below). In these cases the ECD-DCD donors are usually
included among the DCD cohort; thus the use of ‘ECD’
differs from those comparisons where the distinction is
between ECD/non-ECD.
The kidney transplant waiting list
Although the number of active patients on the DD kid-
ney waiting list has increased by 61% between 1996 and
2005, the increase from year to year has slowed from a
high of 10% between 1996 and 1997 to a low of 0.3%
between 2003 and 2004. There was a small increase
in the number of active waiting list patients in the past
2 years, from 45 340 candidates in 2004 to 46 351 in 2005
(roughly a 2% increase). The age distribution of the active
registrants on the kidney waiting list has continued to skew
toward the older age groups, with decreases observed in
the pediatric and young adult age groups. This aging of the
waiting list is important to the discussion of Net Benefit be-
low. The percentage of older adults (ages 50+) on the wait-
ing list has increased steadily from 39.4% in 1996 to 55.8%
in 2005, while the percentages of pediatric and young adult
candidates have declined over the same time period (1.8–
1.1% for pediatrics and 59–43% for adults aged 18–49).
The percentage of active Hispanic/Latino candidates on
the DD kidney waiting list has increased in the past 10
years from a low of 11% in 1996 to a high of 17% in 2005
(Figure 2). In comparison, the percentage of white candi-
dates has slowly declined from a high of 46% in 1996 to
38% in 2005. The gender distribution of active waiting list
registrants has remained constant over the past 10 years
with a higher percentage of male registrants than female
registrants (in 2005, 58% males and 42% females).
At the end of 2005, approximately 74% of the kidney reg-
istrants were actively listed on the DD waiting list and
26% were listed with inactive status. That this percent-
age is greater than the corresponding percentage for the
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Table 1: Kidneys transplanted by donor type, organ type and year of transplant
Donor Type 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Living donor 3668 3927 4419 4716 5488 6035 6240 6470 6647 6563
Deceased donor 7729 7774 8032 8042 8123 8230 8538 8666 9357 9914
Standard criteria donor (SCD) 6558 6519 6707 6680 6786 6806 7018 6929 7442 7554
Expanded criteria donor (ECD) 1076 1137 1219 1218 1174 1177 1230 1344 1378 1609
Donation after cardiac death, non ECD (DCD non-ECD) 82 111 100 127 153 231 264 341 476 677
ECD-DCD 13 7 6 17 10 16 26 52 61 74
Multi-organ Transplants
Kidney-pancreas 848 841 967 930 908 886 902 866 880 895
Kidney-heart 21 20 35 26 29 26 40 29 46 57
Kidney-liver 112 118 98 99 135 134 210 246 279 339
Other 4 7 4 5 3 3 5 5 3 12
Source: Tables 1.7, 1.8, 5.4.
interval of 2001–2004 (18%), is an apparent consequence
of the policy modification that permits accrual of waiting
time while listed as inactive.
Between 1996 and 2005, the number of new kidney wait-
ing list registrations increased from 18 330 to 29 135 (a
59% increase). Between 1997 and 2000, the average an-
nual increase of new kidney waiting list registrations was
between 4% and 6%. From 2003 to 2004, the increase was
11% (24 419 new registrants to 27 126 new registrants)
with an increase of 7% between 2004 and 2005. The me-
dian time to transplant of 1136 days for those candidates
listed in 2002 (the most recent year for which median times
to transplant may be calculated) actually decreased com-
pared with those registered in 2000 (1198 days). However,
the 25th percentile of time to transplant increased from
338 days in 2002 to 355 days in 2005, which presumably
reflects the more recent accelerated increase in new reg-
istrations.
Among new kidney waiting list registrants, large discrep-
ancies in median times to transplants were observed
Source: 2006 OPTN/SRTR Annual Report, Table 5.1a.
Figure 2: Race of active kidney waiting list patients at year-
end, 1996–2005.
among ABO blood types. In 2000 (the most recent year
with sufficient follow-up information available for all blood
groups), the median times to transplant for O, A, B and
AB registrants were 1463 days, 792 days, 1848 days and
469 days, respectively. Because of these discrepancies
in time to transplant, some Organ Procurement Organiza-
tions (OPOs) have adopted a variance in kidney allocation
policy that allocates kidneys from A2 donors to other blood
groups. In 2005, 24 of these transplants were performed,
with 11 going to B recipients, 10 going to AB recipients and
3 going to O recipients. In recent years, graft survival for
these limited numbers of transplants has been reported to
be excellent (1–3).
It is noteworthy that the median time to transplant has de-
creased for pediatric and adolescent registrants aged 6–17
between 2003 and 2005, which may be a result of allo-
cation policy modifications designed to decrease waiting
times for these candidates.
Donor source
The overall number of kidney donors has increased annu-
ally from 8717 in 1996 to 13 266 in 2005. In 2000, the num-
ber of deceased kidney donors was approximately equal
to the number of living kidney donors (5489 DDs com-
pared with 5493 living donors). Between 2001 and 2004,
the number of living kidney donors exceeded the num-
ber of deceased kidney donors. In 2005, the number of
deceased kidney donors surpassed the number of living
kidney donors by 134 donors.
The total number of kidney transplants increased from
14 857 to 15 674 transplants (roughly 5%) between 2003
and 2004. Between 2004 and 2005, the number of kid-
ney transplants increased by a smaller percentage of 2%
or from 15 674 to 16 072 transplants. Increases were ob-
served in all categories of DD kidney transplants with a
modest increase of 2% observed in SCD kidney trans-
plants. A larger increase was observed in DCD, non-
ECD transplants. From 2003 to 2005, the number of
DCD, non-ECD transplants increased at an annual rate of
approximately 40% per year. ECD kidney transplants
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increased from 1378 transplants in 2004 to 1609 trans-
plants in 2005 or a 17% increase. Likewise, the number of
ECD-DCD kidney transplants increased by 21% (from 61 to
74) from 2004 to 2005. After an average annual increase of
approximately 3% in living donor kidney transplants from
2002 to 2004, a slight decrease of 1%, or 84, in living
donor transplants was observed between 2004 and 2005.
Although definitive interpretations cannot be made from
data covering 1 year, following the trend in living donation
over the next several years will be important, especially
given the increases in transplants from DDs.
Living donation accounted for 40.8% of kidney transplants
in 2005. The high rate of living donation has increased at-
tention to the issues of living donor safety in the United
States. The OPTN addresses safety issues through sev-
eral committees, including Membership and Professional
Standards. This committee developed standards for trans-
plant programs to perform living donor kidney transplants
(4). These criteria establish the requirements for open and
laparoscopic donor nephrectomy surgeons and mandate
that a surgeon experienced in open nephrectomy be avail-
able on-site during laparoscopic nephrectomy. The OPTN’s
authority to monitor compliance with these standards and
address instances of noncompliance was clarified in a note
published in the Federal Register on June 16, 2006. This
note states that OPTN living donor guidelines will receive
the same status of other OPTN policies; therefore, non-
compliance with such guidelines will subject the offending
OPTN member to the same consequences as noncompli-
ance with policies concerning deceased organ donors and
deceased organ donor recipients developed under the Final
Rule for operation of the OPTN.
In an effort to expedite reporting of serious events that af-
fect the well-being of living donors, the OPTN Living Donor
Committee recently recommended a requirement for all
transplant centers to report living donor deaths and, for
living liver donors, failure of the liver donor’s native organ
function within 72 h of becoming aware of such events.
This supplements the current routine living donor follow-
up at 6 months and 1 year. The recommendation was ap-
proved by the OPTN Board of Directors for implementation
simultaneously with distribution for public comment (5). It
is currently being implemented.
Over the last several years, living donation has been ad-
vanced using both human leukocyte antigen (HLA) anti-
body and ABO isoaglutinin desensitization/removal tech-
niques. Large series of successful transplants of recipients
with HLA donor-specific alloantibody and/or ABO incom-
patibly to their intended living donor have been described
with protocols utilizing plasmapheresis and low-dose IVIG,
with occasional use of Rituximab (anti-Cd20) (6,7). High-
dose IVIG protocols have also been successful in recipients
with prior positive cross-matches due to HLA alloantibody
against both living donors and DDs.
Nondirected kidney living donation has also increased in
volume through both paired donation, formerly known as
kidney donor exchange, list paired donation or list ex-
change, and simple nondirected donation, usually resulting
in the selection of a recipient with the highest allocation
priority on the local OPTN deceased donation waiting list.
The OPTN Kidney Transplantation Committee has devel-
oped for public comment the concept of a proposed na-
tional Kidney Paired Donation system, as these systems
are most dependent on a large number of participants for
their success. Actual implementation of a Kidney Paired
Donation system through the OPTN would first require
authorization from the HRSA, within the Department of
Health and Human Services (HHS), to proceed with such a
program.
The increases in deceased donation have been aided by
the HRSA-sponsored Organ Donor and Transplantation
Collaboratives. The Organ Donor Breakthrough Collabora-
tive (http://www.organdonationnow.org) has concentrated
on improving relationships between donor hospitals and
OPOs, to increase prompt notification of potential organ
and tissue donors, and to increase consent rates for or-
gan donation. The Organ Transplantation Breakthrough Col-
laborative (http://www.organdonationnow.org/index.cfm?
fuseaction-page.viewpage&pageID-565) brings in the tr-
ansplant centers to help increase the ‘pull’ for organs and
thus organ utilization. It is hoped that improved end-of-life
care with the active involvement of intensivists will im-
prove organ function prior to procurement, and thus graft
function after transplantation. The Collaboratives have set
goals for organs per donor type (SCD vs. ECD vs. DCD)
as detailed in an accompanying article in this report (8).
These goals per donor type help to spread best practices
and have contributed to increased numbers of ECD and
DCD donors across the country. Many OPOs did not previ-
ously have policies in place for DCD donors and have been
assisted by other OPOs to implement DCD policies. One
Collaborative goal is for all DSAs to have at least 10% of
their donors be DCDs. Another area of concentration has
been the use of pulsatile perfusion to evaluate kidney or-
gan function, decrease delayed graft function and increase
the utilization of both ECD and DCD kidneys.
A major goal of the Organ Transplant Breakthrough Collab-
orative is to increase yearly donation from all sources by
7000 kidneys over the current levels, with the objective of
eliminating the kidney transplant waiting list in 10 years.
This target has come to be known as the ‘7000 Kidney
Challenge’. Dr. Alan Leichtman has challenged each DSA
to perform 10 more kidney transplants per month—from
any combination of donor sources. With 58 DSAs in this
country, this would translate into 580 more kidney trans-
plants per month, and therefore 6960 more kidney trans-
plants per year for the country.
It appears currently that the ‘push’ of organs from the Col-
laboratives has been matched, but not exceeded, by the
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‘pull’ from transplant centers. While ECD kidney transplan-
tation is increasing, the significant discard rates for ECD
kidneys have not changed, despite implementation of an
ECD allocation algorithm designed to facilitate placement.
Discard rates for ECD kidneys have not changed apprecia-
bly in this decade. In 2005, 2912 ECD kidneys were recov-
ered with 1169 (40%) discarded. Twenty-five percent of
DCD kidneys recovered were discarded (262 out of 1051),
and 16.6% of SCD kidneys. For the period of January 1,
2001, to July 31, 2004, 36% of recovered ECD kidneys
were discarded, compared with 7% of SCD kidneys and
11% of DCD kidneys (9). The discard rates vary greatly by
DSA, likely influenced by both transplant center practice as
well as local DSA waiting times. There is a negative cor-
relation between recovery rates and discard rates at the
DSA level, i.e. those DSAs with high recovery rates tend
to have lower discard rates.
This profound geographic variation in ECD utilization, which
also exists for SCD and DCD kidneys, suggests that there
are geographic differences in requirements for ECD or
other marginal kidneys. This is consistent with other analy-
ses that indicate there is substantial geographic variation in
access to kidney transplantation from the waiting list. See
the article in this report on Geographic Variability in Access
to Primary Kidney Transplantation for further details (10).
Such variation in both access and utilization suggests that
there are opportunities to distribute kidneys from areas of
low utilization and high candidate access, to those with
high utilization but low access. Efforts by the OPTN and
the SRTR to identify kidneys with a high risk of local dis-
card, and to develop methods to place these kidneys with
centers that are likely to use them, are being undertaken
to minimize these inefficiencies. This is also an opportunity
for the development of better preservation techniques as
well as means of evaluation of renal grafts ex vivo.
The renal transplant community, like all groups, needs clear
terminology for communications of practices and to under-
stand outcomes. The groupings into SCD, ECD and DCD
(defined above) serve this practical purpose; however, all
agree that there is a great amount of heterogeneity within
these groups. ‘Other Criteria Donor (OCD)’ has been pro-
posed by some in the transplant community as a way of
dividing the SCD group into the average ‘standard’ donor,
one that should result in six to eight organs donated, ver-
sus those donors who are less than 50 years old, but have
multiple chronic and/or acute medical issues that result in
a one or two organ donation.
The concept of a continuous donor risk index for kidneys
may help better define ‘the right organ for the right re-
cipient’. While it may be difficult for a predictive formula
created from registry data to capture the experience and
clinical judgment used in evaluating donor organs, a nu-
merical indicator of risk that can be applied by anyone to
any donor at any time may assist the clinician by provid-
ing a reasonable expectation based on past outcomes. A
donor risk index may also be very useful in conveying clini-
cal judgment of physicians to patients in simple terms, for
it is the patient who ultimately accepts these organs. For
organ placement efficiencies, it may allow for individual pa-
tient determination of the risk they are willing to accept at
the time of their listing with alterations allowed over time.
This then will allow the patient to be an active decision
maker in choosing the organ that may be right for them
while not adding cold ischemia time (CIT) to a precious
resource, the donated kidney. This index may also help
to more accurately assess transplant program acceptance
rates. A comparable liver DRI has already been published
that includes donor risk factors to calculate the relative risk
of graft failure: age, cause of death, race, DCD, partial/split,
height, location and CIT (11).
Kidney transplant recipients
In 2005, there was a 6% increase in the total number of DD
kidney transplants performed. Between 2004 and 2005,
increasing numbers of transplants were observed in all DD
categories; SCD: 7442–7554 (2% increase), ECD: 1378–
1609 (17% increase), DCD: 476–677 (42% increase) and
ECD-DCD: 61–74 (21% increase) (Table 1). After a decade
of an upward trend, the total number of living donor kidney
transplants decreased slightly from 6647 in 2004 to 6563
in 2005 (1% decrease).
Recipients of non-ECD kidneys: The yearly increase in
the number of DD non-ECD transplants has recently accel-
erated, increasing from 7270 in 2003 to 7918 in 2004 (9%
increase) and 8231 in 2005 (4% increase). In the preceding
7 years, the average increase was 3% or lower per year.
The age of non-ECD recipients continues to increase. In
2005, approximately half of the non-ECD recipients were
aged 50 years or older at transplant, up from 37% in 1996.
The percentage of recipients aged 18–34 declined from
20% to 14% over the same time period. The percentage
of white recipients decreased from 59% (3882 recipients)
in 1996 to 48% (3972 recipients) in 2005, while the per-
centages of African American and Hispanic recipients in-
creased from 26% (1727 recipients) to 30% (2477 recipi-
ents) and 10% (664 recipients) to 15% (1192 recipients),
respectively. The percentage of zero HLA-mismatched kid-
neys remained relatively stable. The percentage of highly
mismatched kidneys (four or more HLA mismatches) in-
creased dramatically (48% in 1996 to 67% in 2005 com-
pared with a decrease of 37% to 16% for transplants with
one to three HLA mismatches), which reflects both the
overall increase in accrued waiting time points and the
decreased emphasis on HLA matching in allocation policy
over the decade. After a decline between 1997 and 1999,
the percentage of non-ECD kidneys transplanted with CIT
of 21 h or less increased annually from 2000 to 2005.
Recipients of expanded criteria donor kidneys: The
number of ECD kidney transplants increased steadily over
the past decade, from 1089 in 1996 to 1683 in 2005. In
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Source: Sung, et al. Impact of the expanded criteria donor kidney
allocation system on the use of expanded criteria donor kidneys.
Transplantation 2005; 79: 1257-61.
Figure 3: Delayed graft function pre- and post-ECD policy im-
plementation.
2005, 81% of ECD recipients were aged 50 years and older,
an increase from 55% in 1996. The race/ethnicity distribu-
tion of ECD recipients did not change dramatically over the
past decade, although there was a decline of 8% in the
percentage of white recipients. Between 1996 and 2005,
the majority of ECD recipients were male (64% in 2005).
Only 7% of ECD kidneys were transplanted to zero antigen-
mismatched recipients in 2005, compared with 10% in
2001. This probably reflects the 2002 change in allocation
policy for ECD kidneys that decreased the allowable time
interval to place zero-mismatched ECD kidneys nationally.
CIT was under 22 h in approximately 57% of recipients,
which represents an increase of approximately 11% from
2000. Between 2001 and 2005, there was an improvement
in the percentage of ECD kidneys transplanted with a CIT
of less than 12 h, from 11% to 18%. Decreases in CIT for
ECD kidneys are also coincident with the implementation
of the ECD allocation algorithm designed to expedite their
placement. Unfortunately, these improvements in CIT do
not appear to have affected the incidence of delayed graft
function (12) (Figure 3).
Recipients of DCD kidneys: The number of DCD (includ-
ing ECD-DCD) kidney transplants has increased from 95 in
1996 to 751 in 2005. More than 50% of DCD kidney recip-
ients are older than age 50, and only 1% went to pediatric
recipients. The CIT for DCD kidneys has been decreasing;
the percentage of DCD kidneys with CIT less than 21 h
was 58% in 2005 (SRTR Special Analysis, July 2006). This
is likely a consequence of an increased number of DSAs
that have DCD policies in place, and centers that are will-
ing to transplant DCD kidneys, which make them easier to
place.
Multi-organ transplants: The total number of kidneys
transplanted with extrarenal organs continues to increase
(Figure 4) (Table 1). Although the number of combined
kidney-pancreas transplants has not changed appreciably,
heart-kidney and liver-kidney transplants have increased
substantially. The 150% increase in liver-kidney trans-
plants since 2001 is undoubtedly a result of the adop-
Source: 2006 OPTN/SRTR Annual Report, Table 1.8.
Figure 4: Number of combined kidney transplants, 1996–
2005.
tion of MELD based allocation, which gives priority to
those candidates with renal dysfunction based on their
high mortality rates. These candidates receive priority
for donor kidneys over kidney-alone candidates in the al-
location algorithm. Since the indications for liver-kidney
transplantation are not well defined, there is consider-
able debate about the necessity of diverting approximately
3.4% of transplanted DD kidneys to liver-kidney recipi-
ents, and about whether some of these candidates with-
out fixed renal disease might not experience recovery
of native renal function (13,14). Efforts to more clearly
define the indications for liver-kidney are limited by the
lack of large single-center experience, and by insufficient
registry data regarding duration of pretransplant dialysis
and cause of renal disease in liver and liver-kidney candi-
dates.
Recipients of living donor kidneys: The number of living
donor kidney transplants increased dramatically over the
past decade, from 3668 in 1996 to 6563 in 2005, which
represents a 79% increase. As with other types of kidney
transplants, the age distribution of living donor recipients
has shifted toward older recipients; the largest growth was
observed in the percentage of recipients who were aged
50 or older at transplant (24% in 1996 to 43% in 2005).
African Americans and Hispanics continue to be under-
represented in the population of living donor recipients
(35% and 17%, respectively, of the active waiting list at
the end of 2005 compared with 15% and 12% of living
donor recipients in 2005) (Table 2). There continues to be
an increase in the proportion of living donors who are un-
related to the recipient; the percentage of these donors in-
creased from 16% in 1996 to 34% in 2005. This probably
explains the decrease in living donor transplants that had
two or fewer HLA mismatches (32% in 2005, compared
with 45% in 1996).
Deceased donor kidney recipient—graft survival: One-,
3- and 5-year unadjusted graft survivals were 91%,
80% and 70%, respectively, for recipients of DD, non-
ECD kidney transplants. For the same follow-up periods,
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Table 2: Kidneys transplanted by donor type, race and year of transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Deceased donor, non-ECD
Total 6640 6630 6807 6807 6939 7037 7282 7270 7918 8231
White 3882 3789 3784 3782 3738 3695 3753 3610 3885 3972
African American 1727 1832 1852 1861 1977 2072 2120 2148 2340 2477
Hispanic/Latino 664 636 759 769 811 882 970 1015 1110 1192
Asian 294 321 347 313 340 335 357 407 464 483
Other/Multi-race 73 51 64 82 73 53 81 89 119 107
Unknown – 1 1 – – – 1 1 – –
Deceased donor, ECD
Total 1089 1144 1225 1235 1184 1193 1256 1396 1439 1683
White 614 644 667 656 627 633 633 699 679 822
African American 320 317 350 350 353 353 401 459 420 510
Hispanic/Latino 93 119 126 132 113 123 132 139 201 197
Asian 49 57 63 79 77 68 76 83 107 122
Other/Multi-race 13 7 19 18 14 16 14 16 32 32
Living donor
Total 3668 3927 4419 4716 5488 6035 6240 6470 6647 6563
White 2589 2746 3065 3216 3778 4117 4278 4343 4257 4312
African American 524 548 625 720 766 911 903 965 957 958
Hispanic/Latino 413 451 524 546 659 690 746 808 806 792
Asian 102 125 158 162 230 241 227 243 242 253
Other/Multi-race 31 41 27 44 37 60 57 69 75 73
Unknown 9 16 20 28 18 16 29 42 310 175
Source: Tables 5.4a–c.
unadjusted graft survival for ECD transplants was 82%,
68% and 53% (Figure 5).
Among non-ECD recipients, older adults (age 65 years and
older at transplant) had the poorest unadjusted 5-year graft
survival at 60%, followed by adolescents (age 11–17) with
64%, and adults aged 50–64 with 69%. Recipients aged
1–5 had the best long-term graft survival at 76%. African
American recipients had the lowest unadjusted 5-year graft
survival rate of 62% compared with 72% for white recip-
ients, 74% for Hispanic recipients and 78% for Asian re-
Source: 2006 OPTN/SRTR Annual Report, Tables 5.10a, b, c.
Figure 5: Unadjusted 1-, 3- and 5-year kidney graft survival,
by donor type, for transplants received 1999–2004.
cipients. The 5-year graft survival varied by primary diag-
nosis, from 53% for recipients with neoplasms to 80% for
recipients with polycystic kidneys. Diabetic recipients, hy-
pertensive recipients and recipients with renovascular and
other vascular diseases had similar long-term graft survival
at approximately 66%. The 22% of non-ECD kidney re-
cipients who required dialysis within the first week after
transplantation had a 5-year graft survival of 55%, com-
pared with 74% if dialysis was not needed. The 5-year
unadjusted graft survival of non-ECD kidneys decreased
with increasing CIT and increasing number of total HLA
mismatches.
For ECD kidney recipients, similar trends to non-ECD kid-
ney recipients were seen, although the survival percent-
ages are lower. Among age groups, the worst graft out-
comes were also observed in recipients over 65 years;
their unadjusted graft survival was 46% at 5 years.
African American patients continued to fare worse than
other ethnic and racial groups, with 46% graft survival at
5 years compared with 55% for whites, 61% for Hispanics
and 66% for Asians. As with non-ECD kidney transplants,
recipients with a diagnosis of polycystic kidney disease had
the highest unadjusted 5-year graft survival (69%). Diabetic
recipients, hypertensive recipients, recipients with tubular
and interstitial diseases and recipients with renovascular
and other vascular diseases had similarly low graft survival
rates of approximately 48–49%. Graft survival decreased
with increasing CIT and increasing number of total HLA
mismatches.
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∗Adjusted for recipient age, sex, race, PRA, ESRD cause, years
of ESRD, HLA mismatch, year of transplant, previous transplant,
transfusions and donor sex, race, diabetes, cold ischemia time
Source: SRTR Special Analysis, April 2005
Figure 6. Adjusted∗ graft survival for DCD and ECD kidneys,
2000–2004.
Graft survival for DCD kidney transplants was 92% at 3
months, 87% at 1 year, 77% at 3 years and 65% at 5
years. These results are similar to non-DCD transplants.
Even after adjusting for differences in donor and recipient
characteristics, analyses by the SRTR and others have con-
tinued to demonstrate equivalent graft survival between
DCD kidneys and those from brain dead (non-DCD) donors
(Figure 6).
Deceased donor kidney recipients—patient survival:
The annual death rate following non-ECD kidney trans-
plantation has dropped from a high of 60 deaths per 1000
patient-years at risk in 2000 to 43 deaths per 1000 patient-
years at risk in 2004. For ECD transplants, the death rate
has remained relatively stable over the past 3 years at ap-
proximately 100 deaths per 1000 patient-years at risk. Un-
adjusted patient survival rates at 1, 3 and 5 years following
non-ECD and ECD kidney transplantation were 96%, 90%,
83% and 90%, 81%, 69%, respectively (Figure 7).
As expected, patient survival following non-ECD transplan-
tation decreased with increasing recipient age at trans-
plant. Hispanic and Asian recipients had the highest pa-
tient survival of 87% and 88%, respectively, while white
and African American recipients had similar patient survival
(approximately 82%). As with graft survival outcomes, non-
ECD kidney recipients with diagnoses of neoplasms had
the lowest patient survival (approximately 58%). Recipi-
ents of non-ECD kidneys with the longest CIT (42 or more
hours) had worse 5-year survival, 72%, compared with
those with shorter CIT. Unlike non-ECD graft survival, 5-
year unadjusted patient survival did not appear to decrease
with an increasing total number of HLA mismatches.
Unadjusted patient survival trends were similar in ECD
transplant recipients. Five-year patient survival decreased
as recipient age at transplant increased. With an unad-
justed 5-year patient survival of 59%, diabetic recipients
of ECD kidneys had the worst post-transplant patient sur-
vival outcomes. Recipients of ECD kidneys with shorter
CIT had better unadjusted patient survival: 72% for kidneys
with 0–21 h of CIT, 68% for kidneys with 22–31 h and 61%
for those with 32–41 h. Recipients of ECD kidneys from
donors aged 50–64 had better 5-year patient survival than
recipients of older donors aged 65 years and over (71% vs.
64%).
Living donor kidney recipients—graft survival: Graft
survival for living donor kidney recipients continues to be
superior to those for recipients of DD kidneys (Figure 5).
Unadjusted graft survival rates at 1, 3 and 5 years follow-
ing living donor kidney transplantation were 95%, 88% and
80%, respectively. Recipients aged 65 or older had the low-
est 5-year unadjusted graft survival (70%) compared with
other adults aged 18–64 (80%, 82% and 80%, respec-
tively, for age groups 18–34, 35–49 and 50–64). African
American recipients had the lowest 5-year graft survival,
at 72%, compared with approximately 81% for whites,
84% for Hispanics and 87% for Asians. Recipients with
a primary diagnosis of polycystic kidney disease had the
highest 5-year unadjusted graft survival of 88%. Recipi-
ents of older donor kidneys aged 65 or more years had
lower 5-year graft survival at approximately 70% com-
pared with around 80% for other donor age groups. Five
percent of living donor recipients required dialysis within
the first week following living donor kidney transplanta-
tion; these recipients had a 5-year unadjusted graft sur-
vival rate of 51%. Unadjusted 5-year graft survival follow-
ing living donor (related or unrelated) transplantation did not
vary dramatically by relation of the donor to the recipient
(range of 77% for other non-first degree relative to 84% for
sibling).
Living donor kidney recipients—patient survival: After
gradual increases between 1998 and 2001, death rates for
recipients in the first year following living donor transplanta-
tion have decreased, from 26 per 1000 patient-years at risk
Source: 2006 OPTN/SRTR Annual Report, Tables 5.14a, b, c.
Figure 7: Unadjusted 1-, 3- and 5-year kidney patient survival,
by donor type, for transplants received 1999–2004.
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Source: 2006 OPTN/SRTR Annual Report, Table 5.16,
6.16,7.16,8.16.
Figure 8: Prevalence of people living with a functioning
transplant at end of year, 1996–2004.
in 2001 to 21 per 1000 patient-years at risk in 2004. Unad-
justed patient survival rates at 1, 3 and 5 years following liv-
ing donor kidney transplants were 98%, 94% and 90%, re-
spectively (Figure 7). Five-year unadjusted patient survival
decreased with increasing recipient age. Compared with
other primary diagnosis groupings, diabetic living donor
recipients had the lowest 5-year patient survival of 83%
(other diagnoses ranged from 86% to 96%). Recipients
who required dialysis within the first week following living
donor kidney transplantation had a 5-year unadjusted sur-
vival rate of 78% compared with 91% for recipients who
did not require dialysis following transplantation. Recipi-
ents of kidneys from the oldest donors (65 years or older)
had a lower patient survival rate (78%) than recipients of
younger donor kidneys.
Prevalence of people living with a functioning graft:
There were 91 441 renal transplant recipients that entered
2005 with a functioning graft. A continually increasing pro-
portion of these recipients had functioning grafts from
living donors (41%), which reflects the impact of kidney
donor quality on patient survival after transplantation. For
example, 1-year unadjusted patient survival for SCD recip-
ients was 96% in 2004, a slight improvement from 2003,
but still below that of living donor recipients at 97.9%. In
contrast, ECD recipients posted a much lower (90%) 1-year
unadjusted patient survival (Figure 8).
Immunosuppression and acute rejection
Induction immunosuppression: Induction therapy with
biological agents continued a 9-year trend of increasing uti-
lization to 74% of kidney transplants in 2004–2005 (Figure
9). Anti-thymocyte globulin (rabbit) (Thymoglobulin, man-
ufactured by Genzyme Polyclonals S.A.S., Lyon, France,
distributed by Genzyme Corporation, Cambridge, MA) was
used in 39% with the two interleukin-2 receptor (IL2-R)
antagonists, daclizumab (Zenapax Roche, Nutley, NJ) and
basiliximab (Simulect, Novartis, East Hanover, NJ) total-
ing 28%. Alemtuzumab (Campath, manufactured by Gen-
zyme, Cambridge, MA, distributed by Berlex, Montville,
NJ) was used in 9% with the remaining agents, mostly anti-
thymocyte globulin (equine) (ATGAM, Pharmcia & Upjohn
Company, Kalamazoo, MI) and muromonab-CD3 (OKT3,
Ortho Biotech Products, L.P., Bridgewater, NJ) totaling
less than 2%. The practice trend is clearly toward anti-
lymphocyte depleting antibody induction with both Thy-
moglobulin and Campath being the only two agents that
have increased in use over the last 3 years. The interleukin-
2 receptor (IL-2R) antagonists, Zenapax and Simulect, have
declined from a combined 40% usage in 2000 to 2002, to
28% in 2005.
Sixteen percent of the combined recipients from 2001 to
2005 were discharged without maintenance steroids. The
rate of steroid-free maintenance regimens has increased
rapidly in the last 6 years. In 1999, only 3% of recipi-
ents were without steroids at discharge, versus 26% in
2005. In the 2001–2005 recipients, 76% were reported to
have induction therapy with most receiving Thymoglobulin
(43.6%), Campath (14%) or IL2-R antagonists (19%, made
up of Simulect 12% + Zenapax 7%). Over the last 3 years,
several protocols have been published and presented that
describe the use of Thymoglobulin or Campath with five
or less doses of steroids. These protocols have been re-
ferred to as ‘rapid steroid discontinuation’. Most protocols
use the steroids as pre-medication for the Thymoglobulin
or Campath infusions to decrease the chance of cytokine
release syndrome. Campath use was first reported in 2003
when it was used as induction in 10.9% of the steroid-
free maintenance recipients (SRTR special analysis, June
2006). In 2004 and 2005, Campath use in these steroid-
free recipients increased to 17.5% and 20%, respectively.
Thymoglobulin use remains steady at 46% ± 5% for the
last 3 years in these steroid-free maintenance regimens.
Approximately 20% of steroid-free maintenance regimen
Source: 2006 OPTN/SRTR Annual Report, Table 5.6a.
Figure 9: Immunosuppression agents used for induction in
kidney transplantation, 1996–2005.
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recipients are reported to have received no induction ther-
apy from 2003 through 2005.
For 2001 through 2005 discharged patients taking steroids,
Thymoglobulin was the most common single induction
agent (28%), but the two IL2-R antagonists combined were
more frequent at 38% (Simulect 24% and Zenapax 14%).
Campath was used in only 2.1% of these steroid regi-
mens. Thymoglobulin use has doubled in these steroid
maintenance patients from 16.1% in 2001 to 35.9% in
2005.
Maintenance immunosuppression: Only 6% of patients
discharged with a functioning graft were not taking cal-
cineurin inhibitors (CNI) in 2005, with 7% in 2004. For
grafts functioning at 1 year, only 1% were not on a CNI.
This difference from the time of discharge to 1 year could
be due to: (1) patients with delayed graft function be-
ing started on CNIs as outpatients to allow renal func-
tion to return without nephrotoxic drugs, (2) CNIs added
later due to acute rejection on a calcineurin-free regi-
men and/or (3) graft loss in recipients not treated with
CNIs. In 2004, 23% of patients were discharged without
maintenance steroids, with 20% of these patients remain-
ing off steroids 1 year later.
For all 2005 recipients at the time of discharge, cy-
closporine (Neoral®, Novartis, East Hanover, NJ) was used
in 15% of recipients, with tacrolimus (Prograf, Astellas
Pharma US, Deerfield, IL) used in 79% of patients. The
10-year trend for the two CNIs has completely reversed.
A mycophenolic acid (82.2% mycophenolate mofetil, Cell-
cept [Roche, Nutley, NJ] and 4.7% mycophenolate sodium,
Myfortic [Novartis, East Hanover, NJ]) was used in 87%
of recipients at the time of discharge in 2005, a trend
that has continued to increase over the last 10 years. In
2004, 82% of recipients were on a MPA at the time of dis-
charge with that number increasing to 85% 1 year after
transplantation. mTOR inhibitor (Rapamune, Wyeth Phar-
maceuticals Inc, Collegeville, PA, or Certican, Novartis AG,
Basel, Switzerland) use declined at the time of discharge
to 9% in 2005, down from 13% in 2004 and a high of
17% in 2001. However, the use of mTOR inhibitors at 1
year posttransplant is greater than that at discharge, with
18% of 2004 transplanted patients on mTOR inhibitors.
This later introduction of mTOR inhibitors suggests a prac-
tice of transition to lesser nephrotoxic maintenance reg-
imens as an outpatient once a recipient stabilizes after
transplant. This delayed introduction of mTOR inhibitors
could also minimize side effects as lower CNI, steroid, MPA
and/or valganciclovir doses may allow for better tolerability
of the mTOR in regard to hyperlipidemia and bone marrow
suppression.
For patients transplanted in 2004, 81% of patients dis-
charged on tacrolimus plus mycophenolate mofetil with
or without steroids remained on this regimen at 1 year.
For tacrolimus plus sirolimus, this persistency was 60%
at 1 year. Cyclosporine plus azathioprine was maintained
in 85% of patients with cyclosporine plus mycophe-
nolate mofetil at 76% and cyclosporine plus sirolimus
at 71%.
For maintenance regimens without steroids, most patients
were given tacrolimus and a mycophenolic acid. This was
19% of all transplant recipients at discharge in 2005, up
from 14% in 2004. At 1 year, 14% of all patients trans-
planted in 2004 were on only tacrolimus and a mycophe-
nolic acid.
Acute rejection: For patients transplanted in 2004, 12%
were treated for rejection within a year of transplant. The
acute rejection incidence has continued to decrease from
1996 through 2003 with rejection incidences of 51%, 29%,
21%, 19%, 17%, 17%, 15% and 13% in each year, re-
spectively. Steroids were used in 70% of recipients with
rejection; antibodies were used in 48% with 33% receiv-
ing Thymoglobulin (69% of all antibodies used). The trend
of decreasing steroid use and increasing antibody use
that started in 2001 continued. Eight percent of recipi-
ents with acute rejection were treated with an IL2-R an-
tagonist, though there is little in the literature to support
this.
Anticipation of a revised allocation system: net
lifetime survival benefit
Kidney and kidney-pancreas transplant recipients receive
a survival benefit from transplant compared to remaining
on dialysis. Using separate patient survival models for ex-
pected lifetimes following transplant or continuing on dial-
ysis, this benefit can be calculated for individual patients
based on their characteristics. These lifetime calculations
use the survival curves for patients with similar character-
istics based on Cox regression models. These models con-
tain patient (and donor, for post-transplant models) factors
used to estimate median life expectancy with and with-
out transplant. The models to date have considered adult
candidates and recipients. Lifetimes can be recalculated
for each candidate based on the current donor whenever
a new organ becomes available. Aside from active/inactive
status and PRA there is no follow-up reporting mechanism
for kidney waiting list registrants.
Net lifetime survival benefit (NLSB) is calculated by the
expression PT − WL, where PT is posttransplant lifespan
(with transplant), and WL is waiting list lifespan (without
transplant). In the figure shown, this difference in median
survival is 8.3 years for a 25-year-old diabetic candidate,
compared with 3.6 years for a 55-year-old diabetic candi-
date (Figure 10).
Quality of life (QoL) considerations are more relevant to
the assessment of kidney transplant benefit than for other
transplants for which prevention of imminent death is the
primary benefit. Thus, an adjustment is included to account
1368 American Journal of Transplantation 2007; 7 (Part 2): 1359–1375
Kidney and Pancreas Transplantation, 1996–2005
Source: SRTR Special Analysis, June 2006.
Figure 10: Median survival curves for diabetic kidney trans-
plant candidates and recipients, aged 25 and 55.
for the enhancement of QoL provided by a kidney trans-
plant. This quality of life adjusted estimated net lifetime
survival benefit (QENLSB, now referred to as life years
from transplant, or LYFT) values dialysis years (both waiting
list and post-graft failure) less than years with a functioning
graft by a factor of 0.8. Separate studies in published lit-
erature each estimated time-tradeoff factors very close to
0.8 for time spent without versus with a functioning graft
(15,16). All candidates receive the same QoL modifier.
QENLSB can be integrated into a kidney and kidney-
pancreas allocation system, which may maximize the po-
tential benefits of each kidney. Younger candidates tend
to have greater QENLSB scores, but there is a wide range
within each age category (Figure 11). Otherwise, the distri-
bution of QENLSB is similar across DSA at listing, gender,
race/ethnicity, insurance status, and nondiabetic status. Di-
abetic kidney recipients tend to have lower benefit com-
pared with nondiabetics, although the benefit to diabetic
kidney-pancreas recipients is on average greater.
Getting back to basics: supply and demand
This review of renal transplantation in 2005 continues many
of the trends from prior years. Positive trends are improving
or maintaining already excellent patient and graft survival
rates, declining acute rejection rates and increasing main-
tenance regimens without steroids. The ‘white elephant in
the room’ has been growing larger each year—the obvious
problem of supply and demand of a precious resource—
donor kidneys. The manifestation of the organ shortage
is the continued growth of the DD waiting list, leading to
longer waiting times and more deaths on the waiting list
for adults. Nevertheless, efforts to help improve the organ
shortage, focused on both deceased and living donation,
Source: SRTR Special Analysis, November 2005.
Figure 11: Distribution of QENLSB from transplantation with
average SCD kidney, by candidate age (age = 32 years).
have helped to mitigate this increase in the growth of the
waiting list.
The HRSA Organ Donation Breakthrough Collaborative has
already increased organ donation throughout the country.
The number of SCD has slightly increased, with greater
growth potential in older donors (ECD) and donors after
cardiac death (DCD). Kidney, pancreas, liver and lung grafts
from younger DCD donors have excellent function and are
an excellent addition to the organ pool, though so far low
in absolute numbers. While the aging of the population in
the United States is a triumph of modern public health and
medicine, it also has led to the rapid aging of organ donors
over the last 10 years. Since the average ECD kidney trans-
plant has a shorter potential half-life than a non-ECD (either
SCD or DCD/non-ECD) kidney transplant, a more precise
approach is needed to accurately estimate graft survival
when making decisions for candidates. The development
of a continuous donor risk index may help clinicians select
the appropriate ECD kidneys for their patients.
In addition to maximizing timely referrals, consent and con-
version rates for all potential SCD, living donation is the
remaining practical answer for kidney candidates. Living
donor transplantation results in greater patient and graft
survival and longer graft half-lives, with fewer readmissions
and lower levels of immunosuppression use in many pro-
grams. The annual death rate per 1000 patient-years at risk
is less than half for living donor recipients compared to SCD
recipients (21 vs. 43), and one-fifth for those who receive
an ECD graft (21 vs. 104).
In the last 10 years, the number of living donor renal trans-
plants increased from 3668 in 1996 to 6563 in 2005, a
79% increase. During the same period, DD transplanta-
tion increased from 7595 to 9509, a 25% increase. There
are several obvious causes leading to the increase in living
donors: the greater acceptance of unrelated living donors,
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including spouses and friends; the widespread availability
of laparoscopic donor nephrectomy from the late 1990s;
the increasing public awareness of living kidney donation;
and the rapidly increasing waiting time on the DD renal
transplant waiting list. The national median time to trans-
plant has not been able to be calculated since 2002, when
it was 1135 days. The annual death rate on the waiting list
remains about 70 per 1000 patient-years at risk. In 2005,
over 4000 people died on the kidney alone transplant wait-
ing list versus 3000 patient deaths for all the other solid
organs combined.
With 62 294 patients on the waiting list at the end of 2005, it
is imperative that every effort be made to ensure that every
potential willing living donor who is found to be psychoso-
cially fit to donate be allowed to benefit his/her intended
recipient. If this is truly the goal of the health care sys-
tem/transplant community, transplant professionals must
not only work toward a national Kidney Paired Donation
program (donor exchange program), but also seek appro-
priate funding for desensitization programs for both alloan-
tibody incompatible pairs, as well as ABO incompatible
pairs. These programs currently exist in only a few pro-
grams around the country, and growth has historically been
limited by funding constraints.
The next set of goals, to once again increase living dona-
tion rates, must be met by focusing more on the living
donor. While discussion about monetary compensation for
living donors is both controversial and considered by many
to be a violation of the National Organ Transplant Act, there
is an, as yet, unaddressed and growing concern about
the long-term safety of living donors in the United States
which threatens to undermine the growth in living donor
transplantation. Measures to address this could include
the establishment of a database to study long-term living
donor outcomes, lifetime organ-specific health insurance
for donors, coverage of all reasonable expenses related to
organ donation and testing for donation, financial coverage
of post-donation renal function evaluation, and coverage
for all follow-up and long-term care related to the donation.
Adequately addressing these concerns will require coop-
eration and involvement of transplant medical profession-
als, government regulators and private health insurance
payers. For the transplant centers, there will be a need to
create a risk fund to cover the rare, but mathematically ex-
pected, complications that will come from living donation
events.
The commitment to the care of the living donor is much
more difficult for physicians and transplant centers already
faced with financial and logistic obstacles to patient care.
However, it is important to remember that, compared with
dialysis, kidney transplantation not only extends life years
lived and quality of years lived, it also financially benefits
the government, health care providers and insurance com-
panies. To have some of those savings invested in the fu-
ture health of living donors is ethically correct, and would




On May 19, 2006, the Centers for Medicare and Medi-
caid Services (CMS) issued a national coverage determi-
nation that stated that Medicare would now pay for pan-
creas transplantation alone (PTA). This appears in section
260.3 of Pub. 100-03 and can be downloaded at http://
www.cms.hhs.gov/transmittals/downloads/R56NCD.pdf.
CMS will cover PTA performed on or after April 26, 2006
that are reasonable and necessary for Medicare benefi-
ciaries in the following limited circumstances: (1) facilities
must be Medicare approved for kidney transplantation, (2)
patients must have a diagnosis of type I diabetes made
by the documentation of beta cell autoantibody or fasting
C-peptide less than or equal to 110% of the laboratory’s
lower limit of normal, and with a concurrently obtained fast-
ing glucose ≤225 mg/dL, (3) patients must have a history
of medically uncontrollable labile insulin-dependent dia-
betes mellitus with documented recurrent, severe, acutely
life-threatening metabolic complications that require hos-
pitalization, (4) patients must have been optimally and
intensively managed by an endocrinologist for at least
12 months, (5) patients must have the emotional and men-
tal capacity to understand the risks associated with surgery
and the lifelong need for immunosuppression and (6) pa-
tients must otherwise be a suitable candidate for trans-
plantation.
This CMS coverage determination specifically states that
transplantation of partial pancreatic tissue or islet cells is
not covered at this time. CMS has been covering simulta-
neous kidney-pancreas transplantation since July 1, 1999.
Starting October 1, 2004, CMS covered islet cell transplan-
tation only in the context of an NIH-sponsored clinical trial.
The coverage decision discussed the improvement in graft
survival rates in recent years and notes the improvements
in immunosuppressive regimens and surgical techniques,
which have resulted in a decrease in rejection and techni-
cal failure rates (17). Since PTA is generally performed on
patients much less than 65 years old and those not in end-
stage renal diseases, it is unclear how many patients who
would qualify for a PTA are Medicare beneficiaries. How-
ever, this coverage decision may influence more private
payers to cover PTA.
Pancreas utilization
The change in OPTN pancreas allocation policy that went
into effect in February 2005 directs pancreata from donors
older than age 50 or with a body mass index (BMI) greater
than 30 kg/m2 for islet transplantation processing if the
whole organ is not placed locally. This allocation change
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was based on data that demonstrated low placement rates
of such organs for whole pancreas transplantation outside
of the local DSA. This policy change is designed primarily to
expedite placement and decrease CIT for pancreata recov-
ered for islet transplantation, resulting in better utilization
of these organs. The first year under the new policy did not
appear to make a large difference in the number of pancre-
ata recovered for islet processing (70 in 2005 compared
with 73 in 2004). The reason for this may be independent
of allocation issues as financial constraints may have also
affected islet transplant volume nationally.
A major issue in pancreas transplantation in the United
States at the current time appears to be the relative under-
utilization of DD pancreata and the disparate procurement
rates for pancreata from DDs. In 2005, pancreata were not
recovered from 65% of DDs. This rate has been relatively
stable from 2000 to 2005. The pancreas was recovered and
transplanted in 19% of all DDs in 2005, with an additional
5% recovered for transplant but discarded, 2% recovered
for transplant but used for research and 0.9% recovered
for whole organ transplant but used for islets. An additional
3% were recovered primarily for islets and 5% were recov-
ered for research only. This whole organ transplant rate of
19% was slightly down from a high of 24% in 2002 (OPTN
Analysis, April 2006). This may reflect the increasing pro-
portion of older donors mentioned previously.
Among OPTN regions, the percentage of pancreata recov-
ered and transplanted ranged from a low of 10% to a high
of 24%, with a national average of 21% between 2000
and 2005. Regional differences in donor quality could ac-
count for the differences, as well as the number of can-
didates awaiting pancreas transplantation (OPTN Analysis,
April 2006). The overall number of pancreas transplants
ranged from 231 to 1947 across the 11 OPTN regions for a
total of 8456 whole organ pancreas transplants from 2000
to 2005.
The age range of the donor clearly affects the pancreas
utilization rate. From 2000 through 2005, 34% of pancre-
ata from donors less than 18 years old were transplanted,
and 39% from donors aged 18–40 were transplanted. This
rate drops dramatically with only 13% utilized from 41 to
50-year-old donors and 4% from donors aged 51–55. Sur-
prisingly, 1% of donor pancreata from donors aged 56–60
were transplanted (OPTN Analysis, April 2006). Donor BMI
had a similar effect on pancreas utilization, with 26% of
donors with BMI <28 having their pancreata transplanted.
Utilization decreased with increasing BMI, as those with
28–30 had a transplant rate of 15%, 30–35 had a rate of
11%, 35–40 had 6%, and 40+ was 6%.
Reasons for nonrecovery of consented organs in 2005
were 36% due to ‘Poor Organ Function’, 20% due to
‘Other’, 17% for ‘Donor Medical/Social History’ and 11%
for ‘No Recipient Found’. Nine percent of pancreata were
damaged or had anatomic abnormalities that precluded
transplantation. Although the categories above are very
subjective, there is clearly opportunity for increased uti-
lization of the 11% of organs in the category ‘No Recipient
Found’ as these could have been used outside of the local
DSA. The 36% of organs listed as ‘Poor Organ Function’
may offer the opportunity of increased transplantation by
improved and consistent donor management, as well as
cooperative donor management with high volume regional
pancreas centers.
Of pancreata recovered in 2005, 11% were not used due
to ‘No Recipient Found’ with 27% not used due to ‘Other’,
these two reasons account for nearly 40% of the pancreata
recovered and not used. ‘Organ Unsatisfactory’ was listed
in 29% of discards, with ‘Poor Organ Function/Infection’
listed in 14%. Increasing regional and national use of pan-
creata through DonorNet2007 may assist in decreasing dis-
card and nonrecovery rates due to the inability to find an ap-
propriate recipient. Increased training of procurement sur-
geons will undoubtedly also assist the increased recovery
and decreased anatomic injuries reported during pancreas
procurement.
In 2005, 52% of recovered pancreata were transplanted
locally with only 20% of pancreata shared outside of the
local area. However, 13% of the organs recovered for lo-
cal transplantation were not used while only 5% of those
shared were not used. The relatively low demand for pan-
creata in some geographic areas allows the pancreas trans-
plant centers to be very selective in evaluating pancreas
donors. Local variations in pancreas allocation reflect the
diversity of opinion on whether local candidates for simul-
taneous pancreas-kidney (SPK) transplants should be prior-
itized over kidney-only candidates. As a result, differences
in waiting time among DSAs can be several years. Gruess-
ner et al. (18) have previously reported that nearly half the
SPK candidates will die on the waiting list by 4 years if not
transplanted. Type I diabetic recipients of SPK transplants
receive a survival advantage equivalent to a living donor
kidney, and superior to that of a DD kidney alone (19,20).
These observations have convinced many DSAs to prefer-
entially allocate kidneys to SPK candidates in the same
manner as for other combined transplants (liver-kidney,
heart-kidney) independent of their priority on the kidney
waiting list.
The pancreas waiting list
The waiting list for a SPK transplant increased from 1193
active candidates in 1996 to 1194 candidates in 2000. Be-
tween 2000 and 2002, the number of active candidates on
the SPK waiting list was just over 2000. This was followed
by an annual decline in the number of active candidates to
a low of 1536 in 2005. The number of older candidates (age
50–64) increased from 86 (7%) candidates in 1996 to 310
(20%) in 2005. The percentages of African American reg-
istrants (16%) and Hispanic/Latino registrants (11%) also
increased over the past decade.
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The number of patients active on the waiting list at the
end of the year for isolated pancreas transplants has de-
creased from the highs of 534 listed for pancreas after
kidney (PAK) and 303 listed for PTA in 2003 to 330 for PAK
candidates and 209 for PTA candidates in 2005. The ma-
jority of patients awaiting isolated pancreas transplants are
white (83% for PAK, 90% for PTA). Although the percent-
age of PAK candidates aged 50–64 increased dramatically
over the past decade (from 7% in 1996 to 22% in 2005),
a more modest increase was observed in the percentage
of PTA candidates aged 50–64 (11–14%). The percentage
of PAK candidates with previous pancreas/kidney-pancreas
transplants decreased from 43% in 1996 to 26% in 2005.
Overall waiting times continued to increase, with 45% of
the SPK registrants active on the list at the end of 2005
having waited for a year or longer. This was an increase
from 31% at the end of 1996. At the end of 2005, 38% of
candidates on the SPK waiting list were inactive, including
26% of those aged 50 years or older. In 2005, almost 44%
of the inactive waiting list patients had been waiting for 2 or
more years, while only 21% of the active waiting list had
been waiting for 2 or more years. In contrast, a majority
of candidates wait-listed for PAK (66%) and PTA (60%) at
the end of 2005 were not active. A disproportionate per-
centage of inactive wait-listed PAK and PTA candidates had
been waiting 1 or more years at the end of 2005 (72% and
75% inactive vs. 50% and 44% active patients).
The median time to SPK transplant increased to a peak of
543 days for registrants listed in 2000 from 375 days for
registrants listed in 1996. Since 2000, the median time to
transplant has decreased to 428 for registrants listed in
2004. The median time to transplant for registrants listed
in 2004 increased with increasing age, from 374 days for
registrants aged 18–34 years to 432 days for patients aged
35–49 years and 519 days for those aged 50–64. Median
time to SPK transplant was also longer for African Amer-
ican registrants (505 days) and Hispanic registrants (614
days) compared with white registrants (396 days), and reg-
istrants with blood types O and B (535 and 520 days, re-
spectively, in 2004) compared with those with blood types
A and AB (324 and 214 days, respectively). The annual
death rate on the SPK waiting list decreased slightly from
95 per 1000 patient-years at risk in 2004 to 87 per 1000 in
2005.
In 2004, median time to transplant among new PAK reg-
istrations was 575 days while median time to transplant
among new PTA registrations was 376 days. In 2003, white
candidates on the PAK waiting list had shorter median wait-
ing times (461 days) than did African American (740 days)
or Hispanic candidates (863 days). Female PAK and PTA
candidates had longer median waiting times in 2004 (616
and 449 days vs. 486 and 307 days for males). In 2004, PAK
and PTA candidates with blood type O had the longest me-
dian waiting times among ABO blood types. Among can-
didates on the waiting list for PTA in 2005, the death rate
was 61 per 1000 patient-years at risk, while the death rate
among waiting list candidates for PAK was 24 per 1000
patient-years at risk.
Characteristics of pancreas transplant recipients
Although the number of SPK transplants performed in 2005
was 7% lower than the peak of 972 in 1998, the number
of SPK transplants increased over the past 2 years from
871 in 2003 to 881 in 2004 and 903 in 2005. The percent-
age of SPK recipients who were 50 years of age or older
decreased slightly from 19% in 2004 to 15% in 2005. The
majority of SPK recipients in 2005 were white (73%), al-
though the percentage of African American recipients in-
creased from a low of 9% in 2000 to 16% in 2005. SPK
transplant recipients were more often male (62%) in 2005
and only 2% received a zero mismatch transplant. Fewer
than 2% had received a previous kidney-pancreas trans-
plant.
In 2005, 344 PAK transplants and 195 PTA transplants were
performed. This represents an 18% decrease in PAK trans-
plants and a 6% increase in PTA since 2004. The percent-
age of PAK and PTA recipients who were aged 50–64 years
has increased dramatically from 2% and 4%, respectively,
in 1996 to 17% and 19% in 2005. The percentage of African
American PAK recipients has also increased in the past
decade from 3% in 1996 to 10% in 2005. In contrast, the
percentage of African American PTA recipients increased
by only 3% from 1996 to 2005. Increasing numbers of soli-
tary pancreata were transplanted with CIT under 12 h (35%
for PAK and 49% for PTA in 2005 vs. 17% for PAK and 21%
for PTA in 1998).
Pancreas transplant immunosuppression
A majority of pancreas transplant recipients in 2005 (89%
SPK, 85% PAK, 92% PTA) received tacrolimus-based im-
munosuppression for maintenance prior to discharge. Sim-
ilarly, most recipients (81% SPK, 83% PAK, 58% PTA)
had mycophenolate (Cellcept or Myfortic) included in their
maintenance regimen. The use of steroids in maintenance
immunosuppression has decreased from 93% for SPK and
PAK in 2001 to 71% for SPK and 67% for PAK in 2005.
Steroid use is less frequent in PTA recipients, and de-
creased from 77% in 2001 to 52% in 2005.
The overall use of induction agents in pancreas transplant
immunosuppression is increasing, from 62% in SPK recip-
ients and 26% in PAK recipients in 2001, to 88% in SPK
and 83% in PAK in 2005 (SRTR special analysis, August
2006). This may reflect the increasing use of steroid-free
maintenance regimens, as induction is more frequently
used than with steroid-containing regimens (Figure 12). For
example, in 2005, 88% of SPK recipients on steroid-free
regimens received induction; 65% received Thymoglobulin
and 21% received Campath. Campath use in SPK steroid-
free recipients has actually demonstrated a decline in use
from a high of 43.1% in 2004. In contrast, 74% of SPK
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recipients with steroid-containing regimens received in-
duction, with 46% receiving Thymoglobulin and 12%
receiving Campath. The use of anti-CD25 antibodies
(Simulect and Zenapax) was less frequent in steroid-free
regimens (4%) than steroid containing regimens (17%).
Graft survival
Simultaneous pancreas-kidney graft survival—kidney:
Unadjusted kidney graft survival rates at 1, 3 and 5 years af-
ter SPK transplantation were 92%, 85% and 76%, respec-
tively. At 79%, unadjusted 5-year kidney graft survival was
highest for recipients who were aged 35–49 years at trans-
plant compared with 18–34-year-old recipients (72%) and
50–64 year-old recipients (74%). African American kidney-
pancreas recipients had lower 5-year kidney graft survival
(65%) compared with white (78%), Hispanic (80%) and
Asian recipients (77%). Unadjusted 5-year kidney graft sur-
vival was lower for kidney-pancreas recipients who had
received a previous kidney transplant (65% vs. 77% for
those who had not received a previous kidney transplant).
The difference in unadjusted 5-year kidney graft survival
was even larger for kidney-pancreas recipients who had
received a previous pancreas transplant (44% vs. 77% for
those who had not received a previous pancreas trans-
plant). Unadjusted 5-year kidney graft survival decreased
with increasing donor age (78% for 18–34 year-old donors,
73% for ages 35–49 and 66% for ages 50–64).
Simultaneous pancreas-kidney graft survival—
pancreas: Unadjusted pancreas graft survival rates at 1,
3 and 5 years following SPK transplantation were 85%,
79% and 71%, respectively (Figure 13). African American
kidney-pancreas recipients had poorer 5-year pancreas
graft survival (63%) than white (72%), Hispanic (77%)
and Asian (74%) recipients. Unadjusted 5-year pancreas
graft survival was very similar among recipient age groups
(68% for recipients aged 18–34 years, 72% for ages
35–49 and 71% for ages 50–64). As noted above for
kidney graft survival rates, recipients with any previous
Source: 2006 OPTN/SRTR Annual Report, Table 8.6a.
Figure 12: Induction immunosuppression for SPK recipients,
2005.
transplant (kidney, pancreas or both) had worse pancreas
graft outcomes. Five-year pancreas graft survival after
transplants from older adult donors (60% for donors aged
50–64 years) was substantially lower than after trans-
plants from younger adult donors (73% for donors aged
18–34).
Graft survival—PAK and PTA: Unadjusted graft survival
rates at 1, 3 and 5 years following PAK transplantation were
79%, 68% and 56%, respectively. The unadjusted graft
survival rates for PTA at 1, 3 and 5 years following trans-
plantation were moderately lower at 73%, 58% and 53%,
respectively (Figure 13). Five-year graft survival was some-
what better in older PAK and PTA recipients (age 50–64
years: 61% for PAK and 62% for PTA, vs. age 18–34 years:
48% for PAK and 42% for PTA). Surprisingly, no clear trends
in PAK and PTA graft survival were observed by donor age
except for the suggestion of slightly decreased survival for
PTA grafts from donors 35–49 as compared to all other
donors.
Short-term graft survival following solitary pancreas trans-
plantation has improved over the decade, with outcomes
now closer to those for SPK transplants (Figure 14). This
may be a consequence of improved immunosuppression
and improved diagnosis of rejection with increasing use
of biopsy for solitary pancreas transplants. Despite these
improvements, long-term outcomes of solitary transplants
remain worse than for SPK transplants; conditional 5-year
survival (that is, survival of those transplants that were
functioning at 1 year after transplant) for PAK and PTA were
72% and 70%, respectively, compared with 84% for SPK
transplants (SRTR special analysis, August 2006).
Patient survival following pancreas transplant
At the end of 2004, there were 6535 SPK, 1347 PAK and
639 PTA recipients alive with functioning grafts. Over the
past 9 years, death rates for recipients in the first year fol-
lowing SPK transplant have decreased, from 63 per 1000
patient-years at risk in 1996 to 56 per 1000 in 2004. This
Source: 2006 OPTN/SRTR Annual Report, Tables 6.10, 7.10, 8.10.
Figure 13: Unadjusted 1-, 3- and 5-year pancreas graft survival
by transplant type for transplants received 1999–2004.
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Source: 2006 OPTN/SRTR Annual Report, Tables 6.11, 7.11,
8.11b.
Figure 14: Unadjusted 1-year pancreas graft survival, by year
of transplant, 1995–2004.
contrasts with death rates of 96 per 1000 on the SPK wait-
ing list in 2004. The annual death rate per 1000 patient-
years at risk for recipients in the first year following PAK
transplantation was at a 10-year low of 41 in 2004, which
was greater than those on the PAK waiting list (24 per 1000
patient-years at risk). The greater death rate at 1 year af-
ter PAK transplantation versus PAK waiting list is probably
due to short follow-up time. Furthermore, small numbers
of deaths in PTA recipients in the first year following trans-
plantation makes interpretation of annual death rates diffi-
cult. Gruessner et al. have demonstrated a probable benefit
in patient survival in the PAK recipients versus those on the
PAK waiting list with longer follow-up (18). Venstrom et al.
fail to demonstrate a benefit at 4 years (21).
Patient survival rates following all types of pancreas trans-
plantation are excellent. Unadjusted patient survival rates
at 1, 3 and 5 years following SPK transplantation were 95%,
91% and 86%, respectively. The unadjusted patient sur-
vival rates for PAK recipients at 1, 3 and 5 years were 96%,
90% and 84%, respectively (Figure 15). Similar unadjusted
patient survival rates were observed in PTA recipients with
1-, 3- and 5-year patient survival at 95%, 92% and 90%.
African American SPK recipients had only minimally lower
unadjusted 5-year patient survival (83%) compared with
white (86%) and Hispanic recipients (89%). SPK recipients
aged 50–64 years had slightly lower patient survival (82%)
compared with younger recipients (88% for ages 18–34).
Only a slight decrease in patient survival following SPK
was observed with increasing donor age (patient survival
of 87% for donors aged 18–34 to 84% for ages 35–49 to
82% for ages 50–64).
Conclusion
Kidney and pancreas candidates have unique challenges
in the United States today. The large DD kidney waiting
list comprising increasingly older candidates allows both
the opportunity to use ECD grafts due to the shorter life
Source: 2006 OPTN/SRTR Annual Report, Tables 6.14, 7.14, 8.14.
Figure 15: Unadjusted 1-, 3- and 5-year patient survival by
transplant type for transplants received 1999–2004.
expectancy of the candidates, while presenting more ill
patients with less physiological reserve after surgery and
immunosuppression. The superiority of living donor grafts
continues and offers the best overall outcomes. The great-
est challenge to candidates on the DD waiting list is the
increasing median time to transplantation.
The pancreas DD waiting list has slowly decreased since
2000. This may be due to local allocation policies. Type I
diabetics who need to wait more than a couple of years on
a lengthy DD waiting list have a high death rate. Therefore,
many traditional SPK candidates may have turned to life-
saving LD kidney transplantation followed by elective DD
PAK transplantation. The pancreas whole organ grafts ap-
pear to be available throughout parts of the country, but the
potential supply and demand are not ideally geographically
matched.
Children have benefited from recent allocation policy
changes with decreased medial waiting times. The rapid
trend toward steroid-free maintenance immunosuppres-
sion has not resulted in decreased short-term outcomes as
many may have feared. The current struggle with allocation
policy is the attempt to ration a scare resource wisely—the
DD kidney graft. This problem has been mounting annually
despite increases in the numbers of DD kidney transplants
last year, due in large part to the efforts of all those involved
in the HRSA-sponsored Collaboratives. The evaluation of
concepts such as NLSB is attempting to make optimal use
of the donor’s precious gifts, while leaving opportunity for
transplantation to most candidates. In long median waiting
time donor service areas, older candidates have a reason-
able possibility for a kidney transplant via the ECD allocation
system.
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Note on sources: The articles in this report are based on the reference tables
in the 2006 OPTN/SRTR Annual Report, which are not included in this pub-
lication. Many relevant data appear in the figures and tables included here;
other tables from the Annual Report that serve as the basis for this article in-
clude the following: Tables 1.1, 1.3, 1.5, 1.6, 1.7, 3.4, 3.5, 3.6, 5.1a, 5.1b, 5.2,
5.4, 5.4a, 5.4b, 5.4c, 5.6a, 5.6c, 5.6d, 5.6e, 5.6f, 5.6g, 5.6h, 5.6i, 5.7a, 5.7b,
5.7c, 5.10a, 5.10b, 5.10c, 5.14a, 5.14b, 5.14c, 5.15, 5.15a, 5.15b, 5.16, 6.1a,
6.1b, 6.2, 6.3, 6.4, 6.6e, 6.7, 6.10, 6.14, 6.16, 7.1a, 7.1b, 7.2, 7.3, 7.4, 7.6e,
7.7, 7.10, 7.14, 7.16, 8.1a, 8.1b, 8.2, 8.3, 8.4, 8.6e, 8.7, 8.10, 8.14 and 8.16.
All of these tables may be found online at: http://www.ustransplant.org.
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